Business Context and Reporting Period
Company: Arrowhead Research Corporation (a development stage nanotechnology company)
Reporting Period: Quarterly period ended December 31, 2007 (First Quarter of Fiscal 2008)
Business Overview: Arrowhead operates a portfolio of five majority-owned subsidiaries focused on commercializing nanotechnology in life sciences, electronics, and energy. Key subsidiaries include Insert Therapeutics (drug delivery), Calando Pharmaceuticals (RNAi therapeutics), Unidym (carbon nanotubes), Tego BioSciences (fullerene-based pharmaceuticals), and Aonex Technologies (semiconductor nanomaterials). The company also funds sponsored research at universities to secure intellectual property rights.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2007 | Three Months Ended Dec 31, 2006 |
|---|---|---|
| Revenue | $402,861 | $11,092 |
| Cost of Goods Sold | $327,206 | $0 |
| Gross Profit | $75,655 | $11,092 |
| Operating Expenses | $6,960,778 | $4,484,732 |
| Operating Loss | $(6,885,123) | $(4,473,640) |
| Net Loss | $(5,233,774) | $(3,707,170) |
| Cash and Cash Equivalents (Ending) | $25,424,317 | $28,266,834 |
| Total Assets | $30,663,734 | $29,852,952 |
| Accumulated Deficit | $(63,641,211) | $(58,407,437) |
Liquidity: The company reported a net increase in cash of $1.3 million for the quarter, driven primarily by investing activities (proceeds from the sale of stock in a subsidiary) offset by operating cash outflows of $5.8 million. As of December 31, 2007, the company held $25.4 million in cash and cash equivalents.
Debt: The company reported no long-term debt. Current liabilities totaled $2.28 million, primarily consisting of accounts payable, accrued expenses, and payroll liabilities. The company has outstanding loans to its subsidiaries totaling approximately $4.9 million (Insert: $1.0M, Calando: $3.0M, Aonex: $0.9M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $11,092 to $402,861. This was driven by Unidym's operations following its April 2007 merger with Carbon Nanotechnologies, Inc. (CNI), generating $211,845 in product sales and $191,015 in research grants.
- Operating Expenses: Total operating expenses rose by 55% to $6.96 million. Increases were attributed to the expansion of Unidym's manufacturing and R&D capabilities, the continuation of Phase I clinical trials for Insert's IT-101, and preparation for Calando's IND application. Salaries and wages increased by 69% due to hiring new executives and R&D staff.
- Net Loss: The net loss widened to $5.23 million from $3.71 million, reflecting the substantial investment in R&D and operational scaling despite revenue growth.
- Stock-Based Compensation: Stock-based compensation expense increased to $689,590 for the quarter, including a significant inducement grant to the new CEO.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Clinical Progress: Insert Therapeutics is continuing Phase I trials for IT-101 (anti-cancer) with completion expected in 2008. Calando Pharmaceuticals expects to file an Investigational New Drug (IND) application for its lead candidate, CALAA-01, in early-to-mid 2008.
- Capital Resources: Management believes current cash reserves ($25.4 million) are sufficient to fund operations through the fourth quarter of fiscal 2008. The company expects to continue raising capital through equity financing.
- Strategic Merger: On January 14, 2008 (subsequent event), Insert and Calando entered into a merger agreement. If approved, this will consolidate their operations and accelerate capital commitments.
Risks and Contingencies:
- Development Stage Risks: The company has incurred significant losses since inception and expects operating losses to continue until products are commercialized. There is no assurance that drug candidates will receive FDA approval or be commercially successful.
- Capital Needs: Future funding requirements are significant. If additional capital cannot be raised on acceptable terms, the company may need to reduce activities or delay programs.
- Merger Liability: There is a risk that Unidym could be held liable for damages arising from CNI's pre-merger operations.
- Healthcare Reform: Future pricing regulations or reimbursement changes could adversely affect the commercial viability of Insert and Calando's products.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $25.4 million cash balance against the projected $6 million capital commitment to Calando and ongoing R&D burn rates.
- Merger Approval: Confirm the status of the stockholder vote required to approve the merger between Insert Therapeutics and Calando Pharmaceuticals.
- Clinical Milestones: Monitor the timeline and results of Insert's Phase I trial for IT-101 and the filing status of Calando's IND application for CALAA-01.
- Revenue Sustainability: Assess whether Unidym's carbon nanotube sales and grants can scale to offset the high operating costs of the pharmaceutical subsidiaries.
- Equity Dilution: Review the impact of the $50 million shelf registration (Form S-3) declared effective in January 2008 on future share count and dilution.